PARP1 and ovarian carcinoma: In OC maintenance therapy, PARP inhibitors have been shown to significantly prolong the survival of newly diagnosed or platinum-sensitive recurrent ovarian cancer patients, and have become a new treatment paradigm for ovarian cancer.